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Abstract. The present retrospective analysis evaluated the 
efficacy and safety of the VTD (bortezomib, thalidomide, 
dexamethasone) regimen in 205 newly-diagnosed patients with 
multiple myeloma (MM) eligible for high dose therapy and 
autologous stem cell transplantation (HDT/ASCT) in routine 
clinical practice. With a median of 6 cycles (range, 1-8), at least 
partial response was achieved in 94.6% and at least very good 
partial response (VGPR) was achieved in 67.8% of patients. 
Peripheral neuropathy (PN) grade 2-4 was observed in 28.7% of 
patients. In 72% of patients undergoing stem cell mobilization 
one apheresis allowed the number of stem cells sufficient for 
transplantation to be obtained. Following HDT/ASCT the sCR 
rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%. 
The results demonstrated that VTD as an induction regimen 
was highly efficient in transplant eligible patients with MM 
with increased at least VGPR rate following prolonged treat-
ment (≥6 cycles). Therapy exhibited no negative impact on stem 
cell collection, neutrophils and platelets engraftment following 
ASCT. Therapy was generally well tolerated and PN was the 
most common reason of dose reduction or treatment discontinu-
ation.
Introduction
Multiple myeloma (MM) is a lymphoid malignancy 
characterized by clonal expansion of malignant plasma cells 
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producing/secreting monoclonal protein (M-protein) as whole 
immunoglobulin molecules or light chain immunoglobulins 
only. Parameters correlating with negative outcome include 
IgA subtype of M-protein or light-chain multiple myeloma 
(LCMM), advanced disease stage according the International 
Staging System (ISS), high serum ß2-microglobulin and lactate 
dehydrogenase (LDH), low serum albumin and unfavorable 
cytogenetics, such as: t(4;14), t(14;16), and del17p (1,2). 
Treatment of MM has evolved during the last two decades 
which has resulted in unprecedented improvement of patients' 
outcome with increase of the median survival from 3 to 4 years 
to 7-8 years (3). This advancement started in the 1990s with the 
implementation of high-dose therapy followed by autologous 
stem cell transplantation (HDT/ASCT), however the most 
prominent effect for survival is associated with the introduction 
of novel targeted agents, including immunomodulatory drugs 
(IMIDs) and proteasome inhibitors (PIs) (4). The principles 
of MM first line therapy depend on the patients' eligibility 
for HDT/ASCT which is still recommended as a standard of 
care for patients younger than 65-70 years without prohibitive 
comorbidities that achieve at least a partial response for the 
induction therapy (1,5). The efficacy of induction regimen is of 
key significance since the outcome after HDT/ASCT is highly 
related to the depth of response after induction therapy. Another 
important aspect is good tolerability and no negative impact on 
stem cell mobilization. Nowadays, three drug bortezomib-based 
regimens are generally recommended as a standard induction 
therapy for transplant-eligible patients with newly diagnosed 
MM (1,5-7). The choice between different regimens depends 
on drug availability in particular countries, their toxicity 
profile and local preferences. The objective of this retrospective 
analysis was to evaluate efficacy and safety of VTD regimen 
in newly diagnosed MM patients eligible for HDT/ASCT in 
routine clinical practice. 
Materials and methods
Patients. In this retrospective analysis, we collected the data of 
transplant-eligible patients with measurable MM who received 
initial treatment with VTD regimen. Analytical work‑flow taken 
by research group during the study is shown in Fig. 1.
The following inclusion criteria for the study were defined: 
Previously untreated, newly-diagnosed MM, age 18-70 years, 
ECOG performance status <2, patient's compliance with the 
given instructions, life expectancy ≥12 months.
Key exclusion criteria were: Plasma cell leukaemia, 
light‑chain amyloidosis, grade ≥2 peripheral neuropathy (PN) 
or neuropathic pain, severe comorbidities, cardiac insufficiency 
(New York Heart Association (NYHA) >2 grade or left ventric-
ular ejection fraction <60%, known human‑immunodeficiency 
virus (HIV) infection, pregnant, breast-feeding or lactating 
women.
Treatment. VTD regimen recommended by the Polish 
Myeloma Study Group was as follows: Bortezomib at a dose 
of 1.3 mg/m2 administered subcutaneously (SC) or intravenous 
(IV) on days 1, 4, 8, and 11; dexamethasone at a dose 20-40 mg on 
days 1-4 and 9-12; and thalidomide at a dose of 100-200 mg/day 
administered orally. Each cycle should be repeated every 21 days 
for up to 4-6 cycles (8). The analysis included medical records of 
patients who received at least one cycle of VTD. Concomitant 
medications included bisphosphonates, antiviral prophylaxis 
and/or antibiotics in accordance with local practice and deep 
venous thrombosis (DVT) prophylaxis with enoxaparin or 
acetylsalicylic acid (ASA). In patients achieving at least a partial 
response (PR) according to International Myeloma Working 
Group (IMWG) guidelines (9), peripheral blood hematopoi-
etic stem cells (PBSC) were then mobilized according to the 
center's experience and practice. The minimal target yield was 
2x106 CD34+ cells/kg for one transplant. The assumption was to 
obtain a sufficient number of CD34+ cells for two transplants. 
Following induction therapy and effective mobilization, patients 
proceeded to ASCT. The use of a conditioning regimen was left 
at the discretion of each center, as was the decision to conduct 
a single or tandem ASCT and the application of maintenance 
therapy. After transplantation, patients were followed every 
12 weeks until disease progression, and then every 12 weeks for 
survival and subsequent therapies.
The response rates to the induction therapy as well as to the 
consolidation with HDT/ASCT, progression-free survival (PFS) 
and toxicity of the treatment were evaluated. Effectiveness of 
mobilization after VTD-induction therapy was also analyzed. 
The rresponse to the therapy was evaluated according to 
the updated IMWG uniform response criteria (9). Adverse 
events (AEs) were graded by the Common Terminology 
Criteria for Adverse Events, version 4.03. [http://evs.nci.nih.
gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.
pdf].
Statistical analysis. The influence of categorized parameters on 
the response to the treatment and toxicity was performed using 
the Pearson chi square test and exact Fisher test. Associations 
between response and patient characteristics for continuous 
parameters were evaluated using the Mann-Whitney U test. 
Survival curves were estimated by the Kaplan‑Meier method 
and the log-rank test was applied for comparison. PFS was 
defined as the time from introducing the treatment to the last 
date on which the disease activity was assessed, including death 
from any reason. Follow-up time was short to achieve reliable 
results concerning overall survival. The influence of independent 
variables on patient survival was tested by univariate and multi-
variate Cox proportional hazards regression. A multi-parameter 
analysis of factors predicting response to the treatment was also 
performed.
Results
Patients. Between June 2015 and June 2017, a cohort of 205 
consecutive patients qualified for HDT/ASCT were treated with 
VTD as induction therapy in 17 Polish hematology/oncology 
centers. The median age of patients was 59 years (range: 
34-70 years). Advanced clinical stage according ISS 
(International Staging System) (10) was found in 88 patients 
(43%). R-ISS (11) was evaluated in only in 90 patients and 
stage III was found in 20 patients (22.2%). Non-IgG type of 
M-protein was found in 83 patients (40.5%). Cytogenetics was 
evaluated by FISH in 100 patients, with abnormalities found in 
38 patients (38%), including 20 patients with adverse prognostic 
lesions, such as: t(4;14), t(11;14) and abnormalities of 17 chromo-
some. Polyneuropathy was present in 4 patients (1.9%) before 
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the start of VTD therapy. Baseline clinical and laboratory char-
acteristics of the patients are outlined in Table I. 
Treatment. The data on the drug dosage were available for 
184 patients (90%). All the patients started the therapy with the 
standard dose of bortezomib (1.3 mg/m2, in days 1, 4, 8, 11). 
Bortezomib was administered SC in 154 patients (75.1%), IV 
in 41 patients (20%) and 10 patients received bortezomib both 
routes. In 170 patients (92.9%), thalidomide was administered in 
a dose of 100 mg/d and in 11 patients in the dose of 200 mg/d. In 
91 patients (44.3%) the dose of dexamethasone was 160 mg/cycle, 
and in 90 patients (43.9%)-320 mg/cycle. In 90 patients (43.9%) 
VTD was given in 21-day cycles and in 115 patients in 28-day 
cycles (56%). During therapy, all patients received anti-DVT 
prophylaxis. LMWH (low-molecular weight heparin) was used 
in 119 patients (58%) and ASA was used in 70 patients (34.1%). 
Antiviral prophylaxis with acyclovir was used routinely in all 
of patients. The median number of cycles was 6 (range 1-8), 
43 patients received 3-4 cycles (21%), 107 patients received 
5-6 cycles (52%) and 47 patients received 7-8 cycles (23%).
Assessment of response. All 205 patients were available for 
the evaluation of response. ORR was 94.6%, (n=194) including 
32.7% of ≥CR and 67.8% of ≥VGPR. sCR was achieved in 4.9% 
of patients, (n=10), CR in 27.8% (n=57), VGPR in 35.1% (n=72) 
and PR in 27.3% of patients (n=56). Stable disease was observed 
in 2.4% of patients (n=5) and disease progression in 2.4% of 
patients (n=5). In patients with high-risk cytogenetics there was 
a lower rate of CR and sCR as compared to the group without 
these abnormalities (23.8% vs. 30.4 and 0% vs. 10.1%), but not 
statistically significant (P>0.05). There was no significant rela-
tionship between pre-treatment laboratory parameters, steroids 
dose (160 vs. 320 mg), thalidomide dose (200 vs. 100 mg), bort-
ezomib dose and route of administration and the achievement of 
response for the therapy (P>0.05). Response rates were higher 
after ≥6 cycles of VTD as compared to the response rates after 
the 4th cycle, but the difference was not statistically significant 
(P>0.05; Fig. 2). 
Assessment of survival. After the median follow-up of 
18 months, PFS was 83.1%. The only parameter associated with 
longer PFS was the number of administered VTD cycles >4 
(P<0.05; Fig. 3). In patients with renal failure PFS was similar to 
the patients with normal renal function. 
Toxicity. The most common non-hematological grade adverse 
event was PN that occurred in 44.5% of patients (Table II). The 
incidence of PN was similar in patients receiving bortezomib IV 
Figure 1. Analytical work‑flow of the present retrospective study. HDT/ASCT, high‑dose therapy followed by autologous stem cell transplantation; VTD, 
bortezomib, thalidomide, dexamethasone.
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(39%-all grades and 2.44% -severe) and SC (45.5%-all grades 
and 4.55% -severe). VZV (varicella zoster virus) reactivation 
was observed in 3.9% (8/205) of patients. The rates of hemato-
logical adverse events are presented in Table III.
Bortezomib dose was reduced in 42 patients (20.5%). PN was 
the main reason of bortezomib dose reduction (33 patients; 78.6%; 
grade 2 neuropathy with pain-23 patients, grade 3-10 patients), 
among the other reasons there were: Skin changes in 2 patients 
(4.7%), lung fibrosis in 2 patients (4.7%). Severe thrombocyto-
penia and neutropenia were the reason of dose reduction only 
in 1 patient each. Bortezomib treatment was discontinued in 
26 patients (12.7%). The main reasons for discontinuation were 
adverse events (88.4%), including PN in 9 patients (34.6%), 
thrombotic complications (thrombosis, pulmonary embolism) 
in 5 patients (19.2%). Thalidomide treatment was discontinued 
in 3 patient (1.5%) due to polyneuropathy. In 8 (3.9%) patients 
with grade 3 polyneuropathy and 3 (1.5%) patients with grade 2 
polyneuropathy, the dose of thalidomide was reduced to 50 mg. 
On the basis of the exact Fisher test, it was found that there 
was no significant relationship between the dose of steroids (160 
vs. 320 mg), the dose of thalidomide (200 vs. 100 mg), route of 
bortezomib administration (SC vs. IV), duration of cycle (21 days 
vs. 28 days), and toxicity of VTD therapy (P>0.05). However, 
it was shown that in the group of patients in whom the dose 
of bortezomib was reduced, polyneuropathy was statistically 
significantly more frequent (P<0.05; Table IV). No correlation 
between the number of treatment cycles, dose of thalidomide 
and occurrence of polyneuropathy and other adverse events 
Table I. Clinical characteristics of patients treated with the 
VTD regimen.
Parameter Value
Sex, n (%) 
  Female 97 (47.3)
  Male 108 (52.7)
ISS stagea, n (%) 
  1 71 (34.6)
  2 45 (22.4)
  3 88 (43.0)
R-ISS stageb, n (%) 
  1 22 (24.4)
  2 47 (52.2)
  3 20 (22.2)
Protein M type, n (%) 
  IgG 118 (57.6)
  IgA 41 (20.0)
  Light chain MM 39 (19.0)
  IgM 3 (1.45)
Monoclonal light chain, n (%) 
  Kappa 113 (55.1)
  Lambda 88 (42.9)
  Non-secretory 4 (1.95)
Albumin, g/l, median; (min-max) 3.6; (1.8-5.2)
β-2-microglobulin, mg/l,  4.1; (1.58-60.0)
median; (min-max)
Creatinine, mg/dl, median; (min-max) 0.92; (0.37-10.57)
GFR acc. MDRD formula, ml/min, 60; (53-150)
median; (min-max)
Hemoglobin, g/dl, median;  10.9; (6.0-17.3)
(min-max)
Neutrophils, G/l, median; (min-max) 3.2; (0.91-10.1)
Platelets, G/l, median; (min-max) 206; (54-552)
Calcium, mmol/l,  2.39; (1.8-4.77)
median; (min-max)
Monoclonal protein, g/dl,  3.59; (0-14.5)
median; (min-max)
Plasma cells, bone marrow,  37; (0-95)
% median; (min-max)
Cytogenetics, del 17p, t(4;14) t(14;16)  21/100
aISS was evaluated in 204 patients, for one patient data were unavail-
able. bR-ISS was evaluated in 89 patients (43.4%), since cytogenetic 
assessment is not a standard procedure in all hematological centers in 
Poland. ISS, International Staging System; R-ISS, revised International 
Staging System; VTD, bortezomib, thalidomide, dexamethasone.
Figure 2. Association between number of administered VTD cycles and 
response rates. VTD, bortezomib, thalidomide, dexamethasone.
Figure 3. Association between progression-free survival and number of 
administered VTD cycles. VTD, bortezomib, thalidomide, dexamethasone.
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(P>0.05; Table IV). In 3 patients, treatment was discontinued 
because of the lack of efficacy. Six patients died during the 
median 8.56 months follow-up (range 2.8-24.9). There were 
three early deaths and the reasons were sepsis (2 patients after 
2 and 3 cycles of VTD, respectively) and heart failure (1 patient 
after 6 cycles of VTD). One patient died from pneumonia before 
CD34+ cell mobilization, one patient from sepsis after ASCT 
(+59 day) and one due to MM progression (19 months after VTD 
completion).
Results of stem cell mobilization after VTD as an induction 
regimen. Hematopoietic stem cell mobilization was performed 
at the time of analysis in 146 patients (71%). In 63.7% of patients 
(n=93) one apheresis allowed the number of stem cells sufficient 
for transplantation to be obtained. In 20% of patients (n=29) two 
apheresis were performed. The median yield of CD34+ cells 
was 12.6x106/kg (max 70x106/kg) which was sufficient for two 
transplantations in the majority of patients. 
Most commonly used protocols before HSCT mobilization 
were cytosine arabinoside (n=53, 36.3%) and cyclophosphamide 
(n=63; 43.1%). The other protocols included: Etoposide (n=11; 
7.5%); G-CSF alone (n=11; 7.5%); cyclophosphamide with 
etoposide (n=7; 4.8%) and plerixafor (n=1; 0.8%). The median 
yield of CD34+ cells was the highest in patients mobilized with 
cytosine arabinoside. Protocols used before HSCT mobilization 
and their efficacy are presented in Table V. In three patients that 
needed a second procedure of stem cell mobilization, protocols 
with cytosine arabinoside, G-CSF and plerixafor were used and 
the number of HSCT sufficient for the transplant was obtained 
(median 3.56x106/kg; range 3.02-4.1) Table V.
Results of HDT/ASCT after VTD as an induction regimen. 
HDT/ASCT was performed at the time of analysis in 
128 patients with MEL 200 (melphalan 200 mg/m2) protocol 
as conditioning regimen in 87.5% of patients. The other 
conditioning protocols included: MEL 140 (8.6%) and TMI 
(total marrow irradiation) with 12Gy (2.3%); treosulfan+MEL 
(0.8%); TBI+MEL (0.8%).
The median number of transplanted CD34+ cells was 
5.4x106/kg (range: 3.1-10.6x106/kg). The median time to reach 
ANC (absolute neutrophil count) >0.5 G/l and PLT (platelets) 
count >20 G/l were 11 and 12 days, respectively. The most 
common grade ≥3 adverse events observed after HDT/ASCT 
were infections noted in 28 patients (21.9%), including gastro-
intestinal tract infections in 9 patients (7%), mucositis in 
7 patients (5.5%), neutropenic fever in 7 patients (5.5%) and 
sepsis in 3 patients (2.3%). CMV (cytomegalovirus) infection 
was observed in 2 patients (1.6%).
Evaluation of response 100 days after HDT/ASCT was 
performed in 104 patients. Comparing the response rates 
after HDT/ASCT to the responses after the induction, there 
was an increase of ≥CR (50% vs. 32.7%) and ≥VGPR (85.6% 
vs. 67.8%). CR rate increased from 27 to 35.6% and sCR rate 
increased from 4.9 to 14.4% (Fig. 4).
Table II. Non-hematological toxicity of the VTD regimen.
 1-2 grade adverse events 3-4 grade adverse events 
Non-hematological --------------------------------------------------------------------------------- -------------------------------------------------------------------------------
toxicity Number, n Percentage (n=205)  Number, n Percentage (n=205)
Polyneuropathy 
  Grade 1 36 17.6 10  4.9 
  Grade 2 45 33.0 
Infections 8 4.0 2 1.0
Thrombosis 7 3.4 1 0.5
Pulmonary embolism - - 2 1.0
Constipation 2 1.0 - -
Skin alterations 2 1.0 3 1.5
VTD, bortezomib, thalidomide, dexamethasone.
Table III. Hematological toxicity of VTD regimen.
 1-2 grade adverse events  3-4 grade adverse events 
 ------------------------------------------------------------------------------- -------------------------------------------------------------------------------
Hematological toxicity Number, n Percentage (n=205) Number, n Percentage (n=205)
Neutropenia 1 0.5 5 2.5
Thrombocytopenia 4 2.0 1 0.5
Anemia 12 6.0 - -
VTD, bortezomib, thalidomide, dexamethasone.
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Table IV. Assessment of non-hematological and hematological 
adverse events incidence during VTD therapy.
 Occurrence
 --------------------------------------
Analyzed parameter Yes (%) No (%) P-value
Polyneuropathy 
  Number of VTD cycles 
    ≥6 9.7 55.6 >0.05
    <5 6.8 27.8 
  Duration of cycle 
    21 days 9.3 34.6 >0.05
    28 days 7.3 48.8 
  Initial dose of thalidomide 
    200 mg 1.6 4.4 >0.05
    100 mg 14.3 78.6 
    <100 mg 0.55 0.55 
  Bortezomib dose reduction 
    Yes 16.6 3.9 <0.05
    No 0.0 79.5 
Infection 
  Number of VTD cycles 
    ≥6 2.9 62.4 <0.05
    <5 2.0 32.7 
  Duration of cycle 
    21 days 2.9 41.0 >0.05
    28 days 2.0 54.1 
  Initial dose of thalidomide 
    200 mg 0.0 11.0 >0.05
    100 mg 4.0 165 
    <100 mg 0.0 2.0 
  Bortezomib dose reduction 
    Yes 2.0 18.5 >0.05
    No 2.9 76.6 
Thrombosis 
  Number of VTD cycles 
    ≥6 2.9 62.4 >0.05
    <5 1.0 33.7 
  Duration of cycle 
    21 days 2.0 41.9 >0.05
    28 days 2.0 54.1 
  Initial dose of thalidomide 
    200 mg 0.6 5.5 >0.05
    100 mg 1.6 91.2 
    <100 mg 0.0 1.1 
  Bortezomib dose reduction 
    Yes 1.5 19.0 >0.05
    No 2.4 77.1 
Pulmonary embolism 
  Number of VTD cycles 
    ≥6 1.0 64.4 >0.05
    <5 0.0 34.6 
  Duration of cycle 
    21 days 0.0 43.9 >0.05
    28 days 1.0 55.1 
Table IV. Continued.
 Occurrence
 --------------------------------------
Analyzed parameter Yes (%) No (%) P-value
  Initial dose of thalidomide 
    200 mg 0.0 6.0 >0.05
    100 mg 1.1 91.8 
    <100 mg 0.0 1.1 
  Bortezomib dose reduction 
    Yes 0.0 20.5 >0.05
    No 1.0 78.5 
Constipations 
  Number of VTD cycles 
    ≥6 1.0 64.4 >0.05
    <5 0.0 34.6 
  Duration of cycle 
    21 days 0.0 43.9 >0.05
    28 days 1.0 55.1 
  Initial dose of thalidomide 
    200 mg 0.0 6.0 >0.05
    100 mg 0.0 92.9 
    <100 mg 0.0 1.1 
  Bortezomib dose reduction 
    Yes 0.0 20.5 >0.05
    No 1.0 79.5 
Skin alterations 
  Number of VTD cycles 
    ≥6 1.0 64.4 >0.05
    <5 1.5 33.1 
  Duration of cycle 
    21 days 1.0 38.1 >0.05
    28 days 1.5 54.6 
  Initial dose of thalidomide 
    200 mg 1.1 4.8 >0.05
    100 mg 0.5 91.6 
    <100 mg 0.0 0.0 
  Bortezomib dose reduction 
    Yes 0.5 20.0 >0.05
    No 2.0 77.5 
Neutropenia 
  Number of VTD cycles 
    ≥6 2.4 63.0 >0.05
    <5 0.5 34.1 
  Duration of cycle 
    21 days 1.0 42.9 >0.05
    28 days 2.0 54.1 
  Initial dose of thalidomide 
    200 mg 0.55 5.5 >0.05
    100 mg 0.55 92.3 
    <100 mg 0.0 1.1 
  Bortezomib dose reduction 
    Yes 0.0 20.5 >0.05
    No 2.9 76.6 
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Tandem HDT/ASCT was performed in 21 patients with 
suboptimal response to the first course of HDT. Conditioning 
protocols included: MEL200 in 15 patients and MEL140 in 
4 patients, TMI in 2 patients, achieving significant improvement 
in the quality of response (Pearson test, P<0.001) with increase 
of CR to 52.4% (11 patients). 
Discussion
In the era of modern therapies, consolidation with HDT/ASCT 
is still considered as a standard of first line treatment in eligible 
MM patients since evidence from phase 3 studies demonstrated 
the improvement in the depth of response and progression-free 
survival (12,13). Three-drug regimens containing PI and IMID 
were shown to be superior than three-drug regimens with either 
PI or IMID as well as than two-drug regimens in the terms of 
response rates and survival (14-20). Currently in Poland, VTD 
is the most common induction regimen used in about 85% of 
patients, while VCD being used only in the minority of them. 
Our data show that high response rates with ≥VGPR rate of 
67.8% could be achieved with VTD in clinical practice being 
in line with the data from clinical trials where at least VGPR 
ranged from 49 to 69% (14-16,21,22).
However, in phase 3 clinical trial IFM2013-04, at least VGPR 
was achieved in 66.3% of patients after 4 cycles of VTD (16) 
and in retrospective case-matched analysis by Cavo et al (23). 
in 64% of patients treated with 3 cycles of VTD regimen. The 
median number of cycles in our study was 6, so, in clinical 
practice a higher number of VTD cycles was needed to achieve 
results comparable to the clinical studies. There are a few 
possible explanations of these discrepancies. First, there were 
differences in study groups characteristics, like, for example a 
higher percentage of the patients with a more advanced stage of 
MM in the group in our study as compared to the IFM2013-04 
trial. What would be even more important, in our retrospective 
analysis, cytogenetics profile was unknown in about half of the 
patients and as it demonstrated in so far published data, bort-
ezomib could only partially overcome the adverse prognostic 
impact associated with high risk cytogenetics. The results of 
the IFM group study showed that it could eliminate the poor 
risk prognosis of t(4;14) (24), however the data concerning 
del(17p) remain unsatisfactory (14,22,25-29). Another reason 
might be probably the lower median dose intensity caused by 
Table IV. Continued.
 Occurrence
 --------------------------------------
Analyzed parameter Yes (%) No (%) P-value
Thrombocytopenia 
  Number of VTD cycles 
    ≥6 0.5 64.9 >0.05
    <5 1.5 33.2 
  Duration of cycle 
    21 days 2.0 41.9 >0.05
    28 days 0.0 56.1 
  Initial dose of thalidomide 
    200 mg 1.1 4.9 >0.05
    100 mg 0.6 92.3 
    <100 mg 0.0 1.1 
  Bortezomib dose reduction 
    Yes 0.5 20.0 >0.05
    No 1.5 78.0 
  Anemia 
    Number of VTD cycles
    ≥6 2.9 62.4 >0.05
    <5 2.9 31.8 
  Duration of cycle 
    21 days 4.4 39.5 >0.05
    28 days 1.5 54.6 
  Initial dose of thalidomide 
    200 mg 3.3 2.7 >0.05
    100 mg 1.1 91.8 
    <100 mg 0.0 1.1 
  Bortezomib dose reduction 
    Yes 1.5 19.0 >0.05
    No 4.4 75.1 
VTD, bortezomib, thalidomide, dexamethasone.
Figure 4. Evaluation of response following induction therapy, HDT/ASCT 
and double HDT/ASCT. HDT/ASCT, high-dose therapy followed by autolo-
gous stem cell transplantation; PR, partial response; VGPR, very good partial 
response; sCR, stringent complete remission; CR, complete remission; SD, 
stable disease; PD, progressive disease.
Table V. Efficacy of the protocols used prior to HSCT mobi-
lization.
 Yield of CD34+ cells (x106/kg)
 ---------------------------------------------------------------------
Mobilization protocol Median  Minimum Maximum
CPX+G-CSF 9.9 3.1 30.0
VEP +G-CSF 18.0 6.5 55.0
ID-AraC+G-CSF 20.0 3.1 70.0
G-CSF alone 7.2 4.6 17.0
CPX, cyclophosphamide; VEP, etoposide; ID-AraC, cytosine 
arabinoside; G-CSF, granulocyte-colony stimulating factor; HSCT, 
hematopoietic stem cell transplantation.
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more arbitrary approach to dose reduction and discontinuation 
than in clinical trials. The rate of ≥CR after the induction with 
VTD in our study was 32.7% that was much higher than in the 
IFM2013-04 trial (16) and Italian case-matchedanalysis (23). It 
was comparable though to the results obtained in the Spanish 
PETHEMA Group study after 6 cycles of VDT (22), where a 
significant proportion of patients achieved CR during the three 
final cycles. As it was demonstrated by the results of IFM 2005‑01 
trial, achieving at least VGPR before transplant was associated 
with longer PFS (30). So, it might be useful continuing the 
therapy to increase the quality of response especially in patients 
with adverse cytogenetics or in patients in which cytogenetics is 
unknown, like it happens in clinical practice, since achievement 
of less than VGPR was a stronger predictor for progression than 
cytogenetics (30). According to the most recent ESMO guide-
lines 4 to 6 cycles of induction regimen is recommended before 
HDT/ASCT (1). As much as 23% of patients in our retrospective 
analysis received more than 6 cycles of VTD. As we think, this 
could have been related to non-medical conditions, like delayed 
patients' decision on undergoing HDT/ASCT or extended time 
of waiting for transplantation procedure. Lower doses of dexa-
methasone (160 vs. 320 mg) as well as thalidomide (100 vs. 
200 mg) were as effective as the higher ones confirming once 
again that lower, less toxic doses should be preferred (31). 
Among the regimens used in induction treatment in MM 
patients eligible for HDT/ASCT, VRD (bortezomib, lenalid-
omid, dexamethasone) is considered as very effective both in the 
context of response rates (32), as well as the benefit in OS (VRd 
vs. Rd) that was not was observed in case of VTD (17). However, 
lenalidomide is not yet approved in the first‑line therapy of 
patients eligible to HDT/ASCT and the much higher cost of 
VRD compared to VTD would be an issue in some countries. 
In this retrospective analysis, PN grade 2 was reported in 
22% of patients and grade 3 in 4.9% of patients even though 
the median number of cycles was 6. Therefore, grade 2-4 PN 
(26.9%) was lower than expected basing on the results of clinical 
trials (16,33,34). The possible explanation is that in clinical 
practice the grading of neuropathy was determined by the physi-
cians caring for these patients. Presumably hematologists tend 
to minimize or ‘down grade’ these complaints, especially in 
patients that benefit from the therapy. Given the subjective nature 
of grading these symptoms, it would perhaps more helpful to 
look at the number of patients who had to be either dose reduced 
or who discontinued therapy due to neuropathy (20.5%). This 
means that twice weekly bortezomib (given IV or SC) in combi-
nation with thalidomide/dexamethasone leads to significant 
neuropathy. However, PN was the reason for bortezomib discon-
tinuation only in 9/205 patients (4.4%). Thalidomide dose was 
reduced even in fewer patients, (8/3.9%), though according to the 
guidelines, the dose of thalidomide should be reduced first due 
to its irreversibility. It is possible that the dose of 100 mg was 
presumed to be low by the treating physicians and that is why 
they reduced bortezomib first. These observations suggest that 
vigilance for neuropathy should be higher in clinical practice 
since along with prolongation of patients survival its negative 
influence of quality of life is extremely important. It would be 
advisable to include independent neurological assessment in 
patients' management. While lenalidomide may not be avail-
able for first line therapy an easy, less toxic (and perhaps more 
effective) solution may be weekly bortezomib which has been 
shown to lead to less neuropathy and could be potential option 
to improve tolerability. 
In contrast to the results of the phase 3 clinical trial (35), 
but similar to our previous retrospective analysis on VMP in 
clinical practice (36) and also the observations of the other 
authors (37-39) we did not observe the differences in the rate 
of neuropathy between patients receiving bortezomib SC and 
IV. Grade 3/4 non-hematological complications were rare, with 
neutropenia observed only in 2.5% of patients similarly to the 
Italian retrospective analysis by Cavo et al (23) (2%) and much 
lower than in the IFM2013-04 trial 1(8.9%) (16). The lower 
incidence of serious adverse events might result from earlier 
decisions on dose reductions or treatment discontinuation in 
clinical practice than in clinical trials.
In the majority of MM patients undergoing subsequent stem 
cell mobilization, one apheresis procedure was sufficient to 
obtain HSC for two transplants. These results confirm that VTD 
does not negatively impact HSC collection (16,22,40), even 
given at the higher number of cycles. In contrast, lenalidomide 
was reported to adversely impair HSC harvest (41-43), though 
in the more recent retrospective analysis a sufficient number of 
stem cells was obtained in MM patients treated with lenalid-
omide-based regimens (44). In our study, cytosine arabinoside 
that is often used in Polish transplantation centers allowed to 
achieve higher numbers of HSC compared to cyclophospha-
mide, confirming the previous data from retrospective analysis 
of the Polish Lymphoma Research Group (45). Efficient method 
of HSC mobilization was also G-CSF alone.
After HDT/ASCT there was an improvement in the depth 
of response with increase rate of ≥VGPR, CR and sCR. As it 
was demonstrated, achievement of ≥VGPR after transplant has 
a significant effect for prolongation of PFS and OS (46‑49). 
Tandem ASCT allowed for a further increase of CR, similarly 
to the previous reports (50,51). Neutrophils and platelets 
engraftment after ASCT was not impaired in patients treated 
with VCT compared to the other protocols used in induc-
tion (16,22,52). 
This study has some limitations, such as the differences 
in the regimen received by patients (21 vs. 28 day cycles), 
thalidomide/dexamethasone dosing, bortezomib routes 
administration and limited availability of cytogenetics/FISH 
tests that result from retrospective data analysis.
One the other hand, these diversities reflect the manage-
ment of the MM patients in routine clinical practice. In spite 
of VTD extensive evaluation in randomized comparative late 
phase clinical trials, in ‘real world’ MM patient populations are 
much more divergent (53) that affects the clinical outcomes. 
This real-world analysis is very important from the clinical 
point of view, the more so it is the first of its kind in Poland.
In summary, VTD as induction regimen in MM patients 
eligible to ASCT allowed high rates of response to be achieved 
in routine clinical practice, though more cycles were needed 
to obtain results like those in clinical trials. These data 
suggest that in some patients it would be useful to give more 
than 4 cycles to optimize the quality of response, especially 
as the treatment with the median of 6 cycles was well toler-
ated and had no negative impact on stem cell collection or 
hematopoiesis reconstitution after ASCT. However, attention 
should be paid to more adequate neuropathy assessment and 
appropriate bortezomib/thalidomide dose reduction. 
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